Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Research & Development (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Research & Development for 11 consecutive years, with $36.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 1.04% to $36.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $134.7 million through Dec 2025, up 5.74% year-over-year, with the annual reading at $134.7 million for FY2025, 5.74% up from the prior year.
  • Research & Development hit $36.0 million in Q4 2025 for Voyager Therapeutics, roughly flat from $35.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $36.0 million in Q4 2025 to a low of $12.5 million in Q2 2022.
  • Historically, Research & Development has averaged $24.4 million across 5 years, with a median of $24.1 million in 2021.
  • Biggest five-year swings in Research & Development: tumbled 36.26% in 2021 and later skyrocketed 77.01% in 2023.
  • Year by year, Research & Development stood at $14.0 million in 2021, then increased by 3.79% to $14.6 million in 2022, then surged by 77.01% to $25.8 million in 2023, then skyrocketed by 38.15% to $35.6 million in 2024, then increased by 1.04% to $36.0 million in 2025.
  • Business Quant data shows Research & Development for VYGR at $36.0 million in Q4 2025, $35.9 million in Q3 2025, and $31.3 million in Q2 2025.